Chemistry:Levilimab
From HandWiki
Short description: Anti-IL-6 monoclonal antibody
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Clinical data | |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| UNII | |
| KEGG | |
Levilimab is an anti-IL-6 monoclonal antibody initially developed to treat rheumatoid arthritis. In 2020, it was approved as a treatment for COVID-19 in Russia.[1][2][3]
References
- ↑ Harrison, Charlotte (1 August 2020). "Focus shifts to antibody cocktails for COVID-19 cytokine storm" (in en). Nature Biotechnology 38 (8): 905–908. doi:10.1038/s41587-020-0634-9. ISSN 1546-1696. PMID 32760027.
- ↑ Gomon, Y. M.; Strizheletsky, V. V.; Ivanov, I. G.; Balykina, Y. E.; Ermolyev, M. V.; Kolbin, A. S.; Livshits, M. V.; Usmanova, T. A. et al. (2023). "Efficiency of Levilimab in patients with moderate and severe COVID-19." (in ru). pp. 36–47. https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/pt/covidwho-20236125.
- ↑ Lomakin, Nikita V.; Bakirov, Bulat A.; Protsenko, Denis N.; Mazurov, Vadim I.; Musaev, Gaziyavdibir H.; Moiseeva, Olga M.; Pasechnik, Elena S.; Popov, Vladimir V. et al. (December 2021). "The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study". Inflammation Research 70 (10–12): 1233–1246. doi:10.1007/s00011-021-01507-5. ISSN 1420-908X. PMID 34586459.
 |  |
